(Q73287348)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

D1 dopamine receptor activity of anti-parkinsonian drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

G J Fici

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

H Wu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

P F VonVoigtlander

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

V H Sethy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

English

0 references

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

1597-1603

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

Success and problems of long-term levodopa therapy in Parkinson's disease

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Dopaminergic stimulation of subthalamic nucleus elicits oral dyskinesia in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Dopaminergic and non-dopaminergic neurons in the ventral tegmental area of the rat project, respectively, to the cerebellar cortex and deep cerebellar nuclei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

The D1 dopamine receptor in the rat brain: quantitative autoradiographic localization using an iodinated ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Autoradiographic localization of α-bungarotoxin binding sites in the suprachiasmatic region of rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

The activation of inositol phospholipid metabolism as a signal-transducing system for excitatory amino acids in primary cultures of cerebellar granule cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Peripheral pharmacokinetics of apomorphine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

D2 and D1 dopaminergic activity of 7-OH-DPAT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900126-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0024-3205(97)00126-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126882%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference